adefovir dipivoxil; hepatitis B surface antigen; lamivudine resistance; nephrotoxicity; renal transplant recipient Background/Purpose: The emergence of lamivudine (LAM)-resistant mutants after prolonged LAM therapy may reduce its therapeutic effects against hepatitis B virus (HBV). Adefovir dipivoxil (ADV) is an effective treatment of LAM-resistant HBV infections. However, only limited data are available regarding the safety and efficacy of ADV for treating HBsAg-positive renal transplant recipients. Methods: Fourteen HBsAg-positive patients who underwent renal transplantation and developed the YMDD mutation after prolonged LAM therapy were retrospectively analyzed. Five patients were administered ADV monotherapy, while nine patients received ADV plus LAM combination therapy. Data on age, gender, duration of previous LAM treatment, pre-LAM HBV DNA and liver enzyme levels, duration of LAM treatment prior to the emergence of mutations, duration of ADV rescue therapy, and the clinical outcomes of treatment (i.e., normalization of alanine transaminase (ALT) and undetectable HBV DNA levels) were analyzed. Results: The mean age of the patients was 46.8 AE 11.5 years. Males were predominantly studied. The mean follow-up duration of rescue therapy was 38.2 AE 18.3 months. At the beginning of rescue therapy, the mean serum ALT level was 142.2 AE 99.8 IU/mL, while the median serum level of HBV DNA was 7.85 log 10 copies/mL. Patients who received combination therapy tended to demonstrate undetectable serum HBV DNA levels, but no significant differences in * Authorship: CC Lin designed and performed the study, complied and analyzed the data, and wrote the manuscript; TY Chen, CC Chang, and HW Lai performed the study, collected and analyzed the data, and wrote the manuscript; and TH Chen and MC Tsai collected the data and were responsible for the clinical care of the patients. 
Introduction
Immunosuppression seems to enhance the replication of the hepatitis B virus (HBV) and accelerate the progression of liver disease. 1 Flare ups of hepatitis in chronic HBV patients receiving immunosuppressive agents after renal transplantation are common and life-threatening events. 2e4 The persistent suppression of HBV with prolonged antiviral therapy is always mandatory in these patients. Lamivudine (LAM) is considered the drug of choice for the treatment of posttransplant HBV infections and has shown good biochemical and virological responses. 5 However, the emergence of resistant mutants after prolonged LAM therapy for HBV infection may reduce its therapeutic effects. 6 The vast majority of patients with confirmed LAM resistance should receive rescue therapy with antiviral agents that are effective against LAM-resistant HBV mutants. 7 Adefovir dipivoxil (ADV), a nucleotide analog of adenosine monophosphate, is an effective treatment against LAMresistant HBV infections. However, whether or not therapy with combination ADV plus LAM improves the response rate in comparison with ADV monotherapy remains debatable. In a pilot study on patients with compensated chronic HBV and LAM resistance, no differences between HBV DNA suppression and alanine transaminase (ALT) normalization were observed between patients treated with combination LAM plus ADV and patients treated with ADV alone. 8 Recent studies show that switching to ADV alone in patients with LAM-resistant HBV is associated with a higher risk of ADV resistance compared with simply adding ADV to the treatment regimen. 9, 10 However, to date there are limited data available on the efficacy and safety of ADV for treating HBV-positive renal transplant recipients.
In this study, we retrospectively evaluated and compared the therapeutic efficacy and safety of ADV monotherapy and LAM plus ADV combination therapy in LAM-resistant HBsAg-positive renal transplant recipients.
Methods
We retrospectively reviewed the medical records of 765 renal transplant recipients who received regular follow-up visits at Chung Shan Medical University Hospital between January 2003 and December 2007. Twenty-seven HBsAgpositive patients received anti-HBV treatment during the study period. In Taiwan in October 2003, the national healthcare budget only allowed LAM therapy pending HBV reactivation and the presence of necrosis or inflammation of the liver (i.e., salvage treatment). However, since October 2005 ADV has been approved for rescue therapy for the treatment of emerging LAM-resistant HBV infection. Entecavir was not included in the national health insurance (NHI) reimbursement policies as a first-line anti-HBV therapy until October 2008 in Taiwan. Before the start of the treatment, serum creatinine, ALT, total bilirubin, HBV serological markers (i.e., HBsAg, anti-HBs, anti-HBc, HBeAg, and anti-HBe), and serum HBV DNA levels were measured. The renal functions of the study participants were monitored every month, liver function and HBV serology were monitored every 3 months in HBeAg-positive patients, and HBV DNA levels (using polymerase chain reaction [PCR] assay) were monitored every 6 months or whenever otherwise indicated (e.g., the presence of a biochemical breakthrough) to confirm virological breakthroughs. A biochemical breakthrough is defined as an increase in ALT above the upper limit of normal after achieving normalization during continued treatment. A virological breakthrough is defined as an increase in serum HBV DNA by > 1 log 10 (i.e., 10-fold) above nadir after achieving a virological response during continued treatment. Undetectable HBV DNA is defined as a level < 300 copies/mL, as determined using the Roche COBAS Amplicor real-time PCR assay. To analyze LAM-resistant variants, the polymerase gene containing the YMDD motif was amplified using PCR. The presence of YMDD variants was further confirmed by directly sequencing the PCR products. After confirming the emergence of LAM-resistant mutants, rescue therapy (either switching to or adding ADV), as determined by the primary care physician, was initiated. The immunosuppressive protocol was comprised of prednisolone, cyclosporine, and mycophenolate mofetil.
Fourteen patients were identified as showing the emergence of HBV-YMDD mutants. None of these patients had cirrhosis of the liver or hepatocellular carcinoma. Five patients were directly switched to ADV monotherapy. Nine patients received ADV in addition to LAM combination therapy. Data, including age, gender, HBeAg status, time from transplantation to the initiation of LAM therapy, duration of LAM therapy before the emergence of YMDD mutants, HBV DNA levels, and liver enzyme levels before rescue therapy, were recorded for each patient. The time period from switching to or adding ADV to the clinical outcomes of treatment (i.e., ALT normalization at the end of 12 months or undetectable HBV DNA levels at the end of 12 or 24 months of rescue therapy, respectively) were recorded and analyzed. The Roche COBAS Amplicor realtime PCR assay, which has a lowest detection limit of 300 copies/mL, was used to detect virological breakthroughs. All of these patients have been allowed to receive LAM plus ADV therapy since May 2010 when the NHI reimbursement policies were changed.
The serum levels of calcineurin inhibitors (CNIs) were monitored every 3 months. Baseline and changes in renal function during treatment were measured via the estimated glomerular filtration rate (eGFR) using the Cockcroft-Gault formula: [(140-age in years) Â (weight in kilograms) Â (0.85, if female)/(72 Â serum creatinine in mg/dL)] mL/min. If elevated serum creatinine or decreased eGFR were found, the dosage of the CNI was adjusted according to the serum CNI level. Renal biopsy was performed to differentiate between graft rejection, CNI toxicity, and other renal diseases in all of these patients. If all other causes of nephrotoxicity were excluded, ADVrelated nephrotoxicity was considered. The ADV dosage was adjusted according to the eGFR in any case of nephrotoxicity ( Fig. 1) .
All statistical analyses were performed using SPSS software (SPSS for Windows, version 14.0; SPSS Inc., Chicago, IL, USA). Quantitative data are summarized as the mean AE standard deviation (SD) or the median with the range, and the categorical variables are presented as numbers and percentages. The Student t test and Wilcoxon rank sum test were used to compare continuous variables. Fisher's exact test was used to compare dichotomous variables. A p value < 0.05 was considered statistically significant.
This study was performed in accordance with the principles of the 1983 Declaration of Helsinki and was approved by the institutional review board in Chung Shan Medical University Hospital.
Results
Of the 14 patients included in this study, 11 were men and 3 were women. The mean age at the time of renal transplantation was 46.8 AE 11.5 years (range: 26e67 years; Table  1 ). Positive HBeAg status was determined in five patients (35.7%) and negative HBsAg status was determined in nine patients (64.3%). The mean interval from renal transplantation to the start of LAM was 13.8 AE 11.8 months (range: 0.8e46 months). At the time of the initiation of LAM therapy, the mean serum ALT level was 167.4 AE 143.5 IU/mL (range: 39e503 IU/mL) and the median serum HBV DNA level was 8.02 log 10 copies/mL (range: 5.80e9.54 log 10 copies/mL). At the end of 12 months of initial LAM therapy, normalized ALT levels were achieved in 11 patients and serum levels of HBV DNA decreased to undetectable levels in four patients.
The mean period of LAM therapy before the occurrence of a biochemical breakthrough and confirmation of the emergence of resistant mutants was 23.3 AE 10.4 months. The specific primary mutations that confer resistance to LAM included rtM204V þ rtL180M in six patients, rtM204I in four patients, rtM204I þ rtL180M in one patient, rtM204V/I þ rtL180M in one patient, rtM204V in one patient, and rtM204V/I in one patient.
During the beginning of rescue therapy, the mean serum ALT level was 142.2 AE 99.8 IU/mL and the median serum HBV DNA level was 7.85 log 10 copies/mL (range: 5.01e9.23 log 10 copies/mL). The mean follow-up duration of rescue therapy was 38.2 AE 18.3 months. No significant difference was observed in terms of ALT normalization, and undetectable HBV DNA levels were observed in patients who switched to ADV monotherapy and patients who received LAM plus ADV combination therapy (Table 2) . ALT normalization was achieved in 13 patients (92.8%) by the end of the 12-month treatment period. After the sixth month, serum HBV DNA levels in three patients (one in the ADV group and two patients in LAM plus ADV group) declined to undetectable levels. After 12 months of treatment, the median decline in serum HBV DNA was 7.85 (5.01e9.23) to 4.36 (1.07e8.02) log 10 copies/mL (median decline of -4.02 log 10 ), and five patients (one in the ADV group and four patients in the LAM plus ADV group) demonstrated undetectable serum levels. After 24 months of treatment, six patients (one in the ADV group and five patients in the LAM plus ADV group) achieved undetectable serum levels. Seven patients were followed for more than 36 months, and five of these achieved undetectable serum HBV DNA levels. The mean follow-up duration of ADV monotherapy was 32.8 months, and the longest period was 71 months. No virological breakthroughs were observed during the follow-up period in either group. One of the five HBeAg-positive patients achieved HBeAg seroconversion.
Renal dysfunction was diagnosed in eight patients (57.2%) during the follow-up period (Table 3) . A mild decrease in eGFR (5e20%) from the baseline was observed in four patients, a moderate decrease (20e30%) was noted in two patients, and a severe decrease (> 30%) was noted in two patients. Among these, graft rejection was verified in two patients by renal biopsy. CNI toxicity was considered to be the cause of nephrotoxicity in two patients, and the use of immunosuppressive agents was adjusted accordingly. Nephrotoxicity led to a decrease in ADV dosage in three patients (eGFR diminished to 30e50 mL/minute) and withdrawal in one patient (eGFR < 20 mL/min).
Discussion
Although entecavir therapy is safe and efficient for treating HBV-positive organ transplant patients and prophylaxis of HBV reactivation, 11 LAM is the most promising agent for the treatment of HBsAg-positive renal transplant recipients in Asian countries. 5 In our study, in accordance with the NHI reimbursement policies that were in effect during the study period, LAM was not introduced prior to prophylaxis or right after renal transplantation (pre-emptive) until a flare up of hepatitis. By that time, the serum HBV DNA level would be rather high (median: 8.02 log 10 copies/mL), and only 28.5% of patients (in comparison with > 60% of immunocompetent HBV carriers) achieved undetectable serum HBV DNA levels by the end of 12 months of treatment. Conversely, the overall cumulative YMDD mutation rate was 51.8% (14/27) after 23 months of follow-up, which is higher than most other studies. Therefore, it seems better to initiate LAM therapy immediately after renal transplantation, rather than later, when rapid viral replication and overt liver disease have already developed in order to prevent the emergence of YMDD mutants. The ADV resistance rate in patients with LAM resistance can be greatly reduced by addingdrather than switching todADV.
9,10 However, to date, no data on the effectiveness and resistance to ADV are available on HBV-positive renal transplant recipients. In this retrospective study, after a mean follow-up period of 38.2 months we found that a decline in HBV DNA levels of up to 4 log 10 copies/mL could be obtained after 12 months of treatment. Patients who received LAM plus ADV anti-HBV therapy seemed more likely achieve undetectable serum HBV DNA levels after 12, 24, and 36 months (4/9 [44.4%], 6/9 [66.7%], and 4/6 [66.7%], respectively) in comparison with those who received ADV monotherapy; however, mainly due to the small number of cases in this study, these difference are not statistically significant. The decline in the serum HBV DNA level in the ADV monotherapy group was slower than that observed in the combination group, but there were no virological breakthroughs observed in either groups during the study period. In the study by Haziyannis et al, 12 after treatment with adefovir dipivoxil for up to 240 weeks to treat HBeAgnegative chronic HBV patients, the cumulative probability of mutations with virological resistance was 20%, but this probability was only 3% after 96 weeks. Prolonged therapy is associated with the emergence of drug resistance following antiviral treatment for chronic HBV, which usually negates the treatment benefits. 13, 14 It is essential to monitor virological breakthroughs, especially in patients receiving ADV monotherapy, if anti-HBV therapy is to be extended.
The long-term use of ADV has been reported to be associated with a potential risk of nephrotoxicity. 15, 16 In fact, nephrotoxicity is listed as a warning in association with ADV. Graft rejection and the nephrotoxic effects of CNIs (i.e., cyclosporine and tacrolimus) are also major concerns following solid organ transplantation and represent major challenges to patient survival. 17 All of our patients also received CNI-based immunosuppressive therapy after renal transplantation. About 29% of these patients developed moderate to severe renal insufficiency during the follow-up period, and four patients had to decrease or stop ADV therapy due to nephrotoxicity. This may limit the therapeutic efficacy of ADV for the treatment of HBV infection. It is mandatory to closely monitor the renal function of patients receiving combination ADV plus CNI-based immunosuppressive therapy. Switching to new anti-HBV agents with higher genetic barriers and lower nephrotoxicity is recommended to ameliorate the progression of renal insufficiency.
There are some limitations to our study. First, the enrolled population was small and heterogeneous. This is mainly because the strategy for treating LAM-resistant mutants was not standardized during the study period (before 2008). Second, the mean follow-up duration was not long enough to observe the emergence of ADV-resistant mutants because all of the patients were allowed to receive LAM plus ADV therapy since May 2010 when the NHI reimbursement policies were changed.
In conclusion, although no statistical difference was noted, ADV plus LAM combination therapy tends to result in higher therapeutic efficacy over ADV monotherapy for the treatment of LAM-resistant HBV infection in renal transplant recipients. No virological breakthroughs were noted in our patients during the follow-up period; however, nephrotoxicity may limit the therapeutic usefulness of ADV in a significant proportion of patients who have renal dysfunction. Larger clinical trials are needed to confirm these preliminary results. 
